Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CVRx, Inc.CVRX · Entity 6920 | Director | June 01, 2026 | June 03, 2026 |
| Ominto, Inc.OMNT · Entity 164576 | Director | December 08, 2016 | January 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CVRx, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,720 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 8,720 · Balance 8,720 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.43 · Expires 2036-06-01 | Direct | 11,182 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 11,182 · Balance 11,182 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.
Ominto, Inc.
Report date December 08, 2016 · Filed January 12, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-12-07 | Direct | 90,000 |
Reported balance
After 2016-12-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2016-12-08 · Grant · Acquired 70,000 · Balance 90,000 F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors. F2: Reflects the issuance of 70,000 options, which was originally reported on December 13, 2016 as 250,000 options, 180,000 of which were subsequently revoked prior to vesting. F3: Options vest over 30 month period. F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-12-07 | Direct | 120,000 |
Reported balance
After 2016-12-08 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2016-12-08 · Grant · Acquired 30,000 · Balance 120,000 F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors. F5: Options vest as follows: 5,000 options vested on the grant date, the remaining vest at a rate of 1/36 per month. F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an increase to exercise price as determined by the Issuer's Board of Directors.
F2: Reflects the issuance of 70,000 options, which was originally reported on December 13, 2016 as 250,000 options, 180,000 of which were subsequently revoked prior to vesting.
F3: Options vest over 30 month period.
F4: This amendment is being filed to correct the expiration date of the option from the Form 4 dated May 18, 2017.
F5: Options vest as follows: 5,000 options vested on the grant date, the remaining vest at a rate of 1/36 per month.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date October 01, 2024 · Filed October 02, 2024
Section 16 reporting ended · disclosed 2024-10-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,533 |
Ending reported balance
After 2024-10-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-10-01 · Tax withholding · Disposed 331 · Balance 179,269 F1: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Row 2 · 2024-10-01 · Tax withholding · Disposed 616 · Balance 178,653 F2: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Row 3 · 2024-10-01 · Tax withholding · Disposed 662 · Balance 177,991 F3: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Row 4 · 2024-10-01 · Tax withholding · Disposed 458 · Balance 177,533 F4: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,600 |
Reported balance
Holding disclosure · report date 2024-10-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,600 |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021.
F2: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022.
F3: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023.
F4: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2023 Filed Apr 14, 2023 16:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,281 | $64.38 | $146,850.78 |
DisclosureSEC source: 0001127602-23-012934 · form4.xml · nonDerivative · entry 7 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,977 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F7 · price: This transaction was executed in multiple trades at prices ranging from $63.84 to $64.82 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,296 | $62.99 | $144,625.04 |
DisclosureSEC source: 0001127602-23-012934 · form4.xml · nonDerivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,258 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F6 · price: This transaction was executed in multiple trades at prices ranging from $62.62 to $63.44 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 802 | $66.17 | $53,068.34 |
DisclosureSEC source: 0001127602-23-012934 · form4.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,554 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $66.12 to $66.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,000 | $65.60 | $65,600.00 |
DisclosureSEC source: 0001127602-23-012934 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,356 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $65.10 to $66.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,300 | $64.34 | $147,982.00 |
DisclosureSEC source: 0001127602-23-012934 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,356 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.84 to $64.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,398 | $63.01 | $151,097.98 |
DisclosureSEC source: 0001127602-23-012934 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,656 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.61 to $63.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 6,500 | $0.46 | $2,970.50 |
DisclosureSEC source: 0001127602-23-012934 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 647 | $61.74 | $39,945.78 |
DisclosureSEC source: 0001127602-23-012448 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,554 F3 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2023. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 602 | $61.74 | $37,167.48 |
DisclosureSEC source: 0001127602-23-012448 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,524 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:06 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 323 | $61.74 | $19,942.02 |
DisclosureSEC source: 0001127602-23-012448 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,201 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 19:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-23-010145 · form4.xml · derivative · entry 11 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,977 Underlying: Common Stock · 6,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F9 · derivative.exercise_date: Options vested with respect to 25% of the shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment thereafter. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 19:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,950 | $59.06 | $233,287.00 |
DisclosureSEC source: 0001127602-23-010145 · form4.xml · nonDerivative · entry 8 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,035 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F7 · price: This transaction was executed in multiple trades at prices ranging from $58.66 to $59.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 19:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,700 | $58.27 | $99,059.00 |
DisclosureSEC source: 0001127602-23-010145 · form4.xml · nonDerivative · entry 7 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,985 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F6 · price: This transaction was executed in multiple trades at prices ranging from $57.66 to $58.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 19:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 600 | $56.90 | $34,140.00 |
DisclosureSEC source: 0001127602-23-010145 · form4.xml · nonDerivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $56.54 to $57.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 19:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,600 | $59.02 | $271,492.00 |
DisclosureSEC source: 0001127602-23-010145 · form4.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,285 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $58.58 to $59.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 19:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,300 | $58.07 | $75,491.00 |
DisclosureSEC source: 0001127602-23-010145 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,885 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $57.55 to $58.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 19:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 600 | $56.86 | $34,116.00 |
DisclosureSEC source: 0001127602-23-010145 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,185 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $56.54 to $57.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 19:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 6,500 | $0.46 | $2,970.50 |
DisclosureSEC source: 0001127602-23-010145 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 19:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionRestricted Stock Unit · Derivative | 125,393 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-010145 · form4.xml · derivative · entry 10 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,393 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Amount represents the vesting in full of restricted stock units (RSUs) granted under the 2011 Plan in August 2019 that were subject to achievement of certain conditions specified in the award agreement, including continued service to the company. 100% of the RSUs vested on the fourth anniversary of the vesting commencement date as all conditions were satisfied. F8 · derivative.expiration_date: Amount represents the vesting in full of restricted stock units (RSUs) granted under the 2011 Plan in August 2019 that were subject to achievement of certain conditions specified in the award agreement, including continued service to the company. 100% of the RSUs vested on the fourth anniversary of the vesting commencement date as all conditions were satisfied. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 19:05 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 125,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-010145 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 16:51 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantStock Options (Right to Buy) · Derivative | 16,599 | $56.00 Strike: $56.00 | $929,544.00 |
DisclosureSEC source: 0001127602-23-006503 · form4.xml · derivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,599 Underlying: Common Stock · 16,599 shares Expires 2030-02-17 F2 · derivative.exercise_date: These options were granted on February 18, 2023 under the Inari Medical, Inc. 2020 Incentive Award Plan and are scheduled to become vested and exercisable on a quarterly basis commencing April 1, 2023. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 16:51 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 21,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006503 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,892 F1 · shares: 2023 Annual Restricted Stock Units grant ("RSUs"). Vesting Commencement Date begins January 1, 2023, 1/16th of the RSUs shall vest on each quarterly anniversary of the vesting Commencement Date. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-23-005365 · form4.xml · derivative · entry 7 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,477 Underlying: Common Stock · 6,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F7 · derivative.exercise_date: Options vested with respect to 25% of the shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment thereafter. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 603 | $54.15 | $32,652.45 |
DisclosureSEC source: 0001127602-23-005365 · form4.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,480 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $54.10 to $54.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · balance_after: The balance includes 276 shares acquired under the Employee Stock Purchase Plan. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,647 | $53.78 | $303,695.66 |
DisclosureSEC source: 0001127602-23-005365 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,083 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $53.08 to $54.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,014 | $54.11 | $54,867.54 |
DisclosureSEC source: 0001127602-23-005365 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,730 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $54.03 to $54.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,486 | $53.76 | $294,927.36 |
DisclosureSEC source: 0001127602-23-005365 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,744 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $53.03 to $54.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:43 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 6,500 | $0.46 | $2,970.50 |
DisclosureSEC source: 0001127602-23-005365 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 16:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-23-001405 · form4.xml · derivative · entry 8 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,977 Underlying: Common Stock · 6,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F6 · derivative.exercise_date: Option vested with respect to 25% of the underline shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 16:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 100 | $66.79 | $6,679.00 |
DisclosureSEC source: 0001127602-23-001405 · form4.xml · nonDerivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,454 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 16:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,635 | $66.10 | $174,173.50 |
DisclosureSEC source: 0001127602-23-001405 · form4.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,554 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $65.79 to $66.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 16:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 3,515 | $66.44 | $233,536.60 |
DisclosureSEC source: 0001127602-23-001405 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,189 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.78 to $65.72 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 16:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 2,213 | $66.25 | $146,611.25 |
DisclosureSEC source: 0001127602-23-001405 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,704 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $65.96 to $66.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 16:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,287 | $65.55 | $281,012.85 |
DisclosureSEC source: 0001127602-23-001405 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,917 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.96 to $65.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 16:50 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 6,500 | $0.46 | $2,970.50 |
DisclosureSEC source: 0001127602-23-001405 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 18:39 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 509 | $63.56 | $32,352.04 |
DisclosureSEC source: 0001127602-23-000712 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,704 F2 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2022. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 18:39 UTC | Inari Medical, Inc. NARI · Entity 83035 | Tax withholdingCommon Stock | 273 | $63.56 | $17,351.88 |
DisclosureSEC source: 0001127602-23-000712 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,213 F1 · shares: Consists of shares of common stock retained by Inari to satisfy the reporting person's tax obligation in connection with the vesting of restricted share units awarded in 2021. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-22-027452 · form4.xml · derivative · entry 7 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,477 Underlying: Common Stock · 6,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F6 · derivative.exercise_date: Option vested with respect to 25% of the underlying shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment there after. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,250 | $69.72 | $366,030.00 |
DisclosureSEC source: 0001127602-22-027452 · form4.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,486 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $69.32 to $70.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,000 | $68.87 | $68,870.00 |
DisclosureSEC source: 0001127602-22-027452 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,736 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $68.24 to $69.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 5,400 | $69.72 | $376,488.00 |
DisclosureSEC source: 0001127602-22-027452 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,736 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $69.24 to $70.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,100 | $68.87 | $75,757.00 |
DisclosureSEC source: 0001127602-22-027452 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,136 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.24 to $69.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:22 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 6,500 | $0.46 | $2,970.50 |
DisclosureSEC source: 0001127602-22-027452 · form4.xml · nonDerivative · entry 1 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001127602-22-025778 · form4.xml · derivative · entry 9 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,977 Underlying: Common Stock · 6,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F8 · derivative.exercise_date: Option vested with respect to 25% of the underlying shares on April 30, 2020 and vests with respect to the remaining shares in 36 equal monthly installment thereafter. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 607 | $80.02 | $48,572.14 |
DisclosureSEC source: 0001127602-22-025778 · form4.xml · nonDerivative · entry 7 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,736 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F7 · price: This transaction was executed in multiple trades at prices ranging from $79.89 to $80.24 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,243 | $79.28 | $336,385.04 |
DisclosureSEC source: 0001127602-22-025778 · form4.xml · nonDerivative · entry 6 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,343 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F6 · price: This transaction was executed in multiple trades at prices ranging from $78.87 to $79.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,400 | $78.33 | $109,662.00 |
DisclosureSEC source: 0001127602-22-025778 · form4.xml · nonDerivative · entry 5 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,586 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $77.85 to $78.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 715 | $80.00 | $57,200.00 |
DisclosureSEC source: 0001127602-22-025778 · form4.xml · nonDerivative · entry 4 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,986 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $79.83 to $80.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 4,384 | $79.25 | $347,432.00 |
DisclosureSEC source: 0001127602-22-025778 · form4.xml · nonDerivative · entry 3 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,701 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $78.83 to $79.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 16:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 1,401 | $78.28 | $109,670.28 |
DisclosureSEC source: 0001127602-22-025778 · form4.xml · nonDerivative · entry 2 Hill, Mitch C. · CIK 0001644989 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,085 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.83 to $78.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.